Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Petrozza, Vincenzoa; 1 | Costantini, Manuelab; 1 | Tito, Claudiad; 1 | Giammusso, Laura Mariac | Sorrentino, Veronicaa | Cacciotti, Jessicaa | Porta, Natalea | Iaiza, Alessiac | Pastore, Antonio Luigid | Di Carlo, Angelinae | Simone, Giuseppeb | Carbone, Antoniod; 2 | Gallucci, Micheleb; f; 2 | Fazi, Francescoc; 2; *
Affiliations: [a] Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Pathology Unit ICOT, Latina, Italy | [b] Department of Urology, IRCCS – Regina Elena National Cancer Institute, Rome, Italy | [c] Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Section of Histology and Medical Embryology, Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza University of Rome, Rome, Italy | [d] Department of Medico Surgical Sciences and Biotechnologies, Sapienza University of Rome, Urology Unit ICOT, Latina, Italy | [e] Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy | [f] Department of Urology, Sapienza University of Rome, Rome, Italy
Correspondence: [*] Corresponding author: Francesco Fazi, Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Section of Histology and Medical Embryology, Sapienza University of Rome, Via A. Scarpa, 14-16, 00161 Rome, Italy. Tel.: +39 6 49766575; Fax: +39 6 4462854; E-mail: francesco.fazi@uniroma1.it.
Note: [1] These authors have contributed equally to this work.
Note: [2] Co-last authors.
Abstract: BACKGROUND: MicroRNAs (miRNAs) are emerging as promising molecules in the diagnosis, prognosis and treatment of urological tumours. Recently, our group performed two independent studies highlighting that miR-210-3p may be a useful biomarker not only for diagnosis but also for post-surgery clear cell Renal Cell Carcinoma (ccRCC) management. OBJECTIVE: The aim of this study is to further explore the effectiveness of miRNA as non-invasive biomarker for clinical outcomes and ccRCC response to the treatment. METHODS: We analyzed miR-210-3p levels in neoplastic and healthy tissue and in urine specimens collected at surgery and during follow-up of 21 ccRCC patients by RTqPCR. RESULTS: Firstly, we confirmed that the expression of miR-210-3p was upregulated in tumor tissues and in urine samples of analyzed cohort. Of note is that miR-210-3p expression was significantly reduced in urine samples from disease-free patients during follow-up (from 3 to 12 months) compared to the baseline levels observed at the time of surgery. In a small subgroup of patients presenting metastatic progression (such as bone, intestinal or lung metastasis), the urine levels of miR-210-3p correlated with responsiveness to the therapy. CONCLUSIONS: This pilot study highlights the relevance of secreted miR-210-3p as powerful non-invasive prognostic and predictive biomarker for the evaluation of clinical outcomes and treatment response during ccRCC follow up.
Keywords: microRNA, miRNA, ccRCC, Cancer biomarkers, Liquid biopsy, metastasis, m miR-210
DOI: 10.3233/CBM-190242
Journal: Cancer Biomarkers, vol. 27, no. 2, pp. 181-188, 2020
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl